Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2022 Earnings Call Transcript

Ed White: Okay. And perhaps just looking at the other indications you mentioned today, Idiopathic Short Stature and Prader-Willi Syndrome. For ISS, would you be looking for an Asian partner? And would you be — how are you thinking about the timing to the start of a trial. Would this be a 2023 event or a 2024 event?

Richard Hawkins: As we haven’t guided on the start of such a study, I think it’s pretty obvious that there would be a number of partners there who would be interested in talking to us. Other than that, I mean, it’s pretty obvious that ISS is of high importance and expanding importance around the world, especially in Asia. John, do you have anything to add to that?

John McKew: No, I think that’s a great answer.

Operator: Our next question comes from the line of Yasmeen Rahimi with Piper Sandler.

Unidentified Analyst: This is on for Yas. First of all, congrats on completing enrollment. We just want to ask — so could you help us understand now that enrollment is complete, where you guys ended up in regards to baseline characteristics like age, MPH, starting high? And are you confident that the having outliers have been minimized, just some clarification on that.

Richard Hawkins: Good question, Lauren. And John, do you start with that answer?

John McKew: Sure. So we announced our last patients enrolled last night. So we’re working on finishing the baseline characteristics analysis for that data, and we would anticipate releasing that bigger data set at an medical conference. So I’ll just reiterate that at our interim analysis, we also released 75% enrolled baseline characteristic data, and we saw a nice shift between 50% and 75%. And then the expectations, particularly for age, are that those are going to continue to come closer together. Randomization will be more effective as we go from 75% to 100%. But we’re in the process of working through that data now.

Operator: And showing no further questions. This does conclude today’s question-and-answer session. Ladies and gentlemen, this also does conclude today’s conference call. You may now disconnect. Everyone, have a great day.